Table 3 Molecular immunohistochemical indexs
From: Analysis of risk factors and prognosis of 253 lymph node metastasis in colorectal cancer patients
253 lymph node negative group (n = 381) | 253 lymph node positive group (n = 10) | P | |
|---|---|---|---|
Ki67 | 74.5% ± 15.6 % | 79.0% ± 8.8 % | 0.371 |
MSH2 | 79.4% ± 12.7 % | 75.5 ± 11.7 | 0.340 |
MSH6 | 78.9% ± 13.1 % | 68.0% ± 26.1 % | 0.013 |
MLH1 | 72.5% ± 15.6 % | 56.5% ± 24.3 % | 0.002 |
PMS2 | 70.9% ± 17.8 % | 60.0% ± 21.2 % | 0.059 |
MMR | 0.602 | ||
DMMR | 9 (2.7%) | 0 (0.0%) | |
PMMR | 330 (97.3%) | 10 (100.0%) | |
HER1 | 0.813 | ||
Negative | 42 (12.5%) | 1 (10.0%) | |
Positive | 294 (87.5%) | 9 (90.0%) | |
HER2 | 0.647 | ||
Negative | 89 (27.1%) | 3 (30.0%) | |
+ | 157 (47.7%) | 3 (30.0%) | |
++ | 81 (24.6%) | 4 (40.0%) | |
+++ | 2 (0.6%) | 0 (0.0%) | |
KRAS | 0.965 | ||
Wild type | 72 (65.5%) | 2 (66.7%) | |
Mutant type | 38 (34.5%) | 1 (33.3%) | |
NRAS | 0.678 | ||
Wild type | 104 (94.5%) | 3 (100.0%) | |
Mutant type | 6 (5.5%) | 0 (0.0%) | |
BRAF | 0.869 | ||
Wild type | 110 (99.1%) | 3 (100.0%) | |
Mutant type | 1 (0.9%) | 0 (0.0%) | |
PIK3CA | 0.813 | ||
Wild type | 107 (98.2%) | 3 (100.0%) | |
Mutant type | 2 (1.8%) | 0 (0.0%) |